인슐린 패치 펌프 시장 : 제품 유형, 당뇨병 유형, 동작 모드, 장착 기간, 환자 연령층, 최종 사용자, 유통 채널별 - 세계 시장 예측(2026-2032년)

The Insulin Patch Pumps Market is projected to grow by USD 2.95 billion at a CAGR of 11.12% by 2032.

Insulin patch pumps are wearable, tubeless insulin delivery devices designed to provide continuous subcutaneous insulin infusion without conventional pump tubing. The category sits at the intersection of diabetes technology, connected medical devices, and patient-centered drug delivery, serving people with insulin-requiring diabetes who need flexible basal and bolus dosing.

Demand is supported by the documented global diabetes burden. The International Diabetes Federation reported 537 million adults living with diabetes in 2021 and projected 643 million by 2030, while the CDC reported 38.4 million people with diabetes in the United States in 2021. Against this backdrop, insulin patch pumps are gaining relevance because they can reduce injection burden, support discreet dosing, and integrate with continuous glucose monitoring and digital health platforms.

Transformative Shifts in the Insulin Patch Pump Landscape

The insulin patch pump landscape is shifting from standalone infusion hardware toward connected, algorithm-enabled therapy ecosystems. Tubeless designs, smartphone interfaces, cloud-based data sharing, and CGM integration are changing how patients, clinicians, and caregivers manage insulin therapy between clinic visits.

Regulatory momentum and real-world adoption are also reshaping competition. FDA-cleared automated insulin delivery systems have demonstrated how interoperable pumps, CGMs, and dosing algorithms can improve time-in-range for many users. At the same time, payers are evaluating device coverage through evidence on glycemic outcomes, hypoglycemia reduction, adherence, training requirements, and total cost of diabetes care.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating cumulative value across insulin patch pumps by improving dosing decision support, personalization, device monitoring, and patient engagement. In closed-loop and hybrid closed-loop systems, algorithmic models use CGM data, insulin-on-board, meal inputs, and activity patterns to adjust insulin delivery within defined safety parameters.

The most practical AI opportunities are evidence-driven rather than speculative. Predictive alerts for hyperglycemia or hypoglycemia, anomaly detection for occlusion or site failure, remote population monitoring, and behavioral coaching can help clinicians focus on patients at higher risk. Responsible deployment requires transparent validation, cybersecurity controls, bias testing across age groups and ethnic populations, and compliance with medical device software regulations.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East, and Africa

North America remains a high-adoption region for insulin patch pumps due to established endocrinology networks, CGM penetration, reimbursement pathways, and extensive FDA experience with automated insulin delivery systems. The United States is particularly influential because device clearances, payer coverage policies, and clinical guidelines often shape global product strategies, while Canada's publicly administered healthcare structure supports clinical use with province-level variation in access.

Europe benefits from advanced diabetes care infrastructure, strong clinical guideline adoption, and national reimbursement systems, although uptake varies by country and health technology assessment outcomes. The European regulatory environment under the Medical Device Regulation places higher emphasis on clinical evidence, post-market surveillance, and software lifecycle management, which is especially relevant for connected insulin patch pumps and algorithm-enabled delivery.

Asia-Pacific is expanding in clinical relevance because China and India carry some of the world's largest diabetes populations, while Japan, South Korea, and Australia have strong digital health readiness, specialist capacity, and familiarity with diabetes technology. Latin America shows growing need in countries such as Brazil and Mexico, but access remains shaped by affordability, reimbursement depth, and public-sector procurement. The Middle East, particularly Gulf economies, is supported by high diabetes prevalence and investment in specialty care, whereas Africa faces the widest access gaps due to insulin affordability, limited specialist coverage, and uneven medical device reimbursement.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

The G7 markets are central to insulin patch pump commercialization because they combine advanced regulatory systems, large insured populations, specialist diabetes care networks, and established adoption of continuous glucose monitoring and automated insulin delivery technologies. The European Union adds scale through harmonized medical device regulation under the EU MDR, although country-level reimbursement, clinical eligibility criteria, and health technology assessments remain decisive for uptake.

BRICS countries represent a major long-term demand base because of large diabetes populations in China, India, Brazil, Russia, and South Africa, but successful expansion depends on affordability, local evidence generation, service support, and tiered access models. ASEAN markets are heterogeneous, with Singapore and Malaysia better positioned for premium connected diabetes devices than lower-income members, while Indonesia, Thailand, Vietnam, and the Philippines present need that is more dependent on reimbursement reform and specialist access.

GCC countries benefit from high diabetes prevalence, national health investments, and expanding specialty endocrinology services, supporting interest in wearable insulin delivery and remote monitoring. NATO alignment is less a demand indicator than an operational lens, with member economies placing increasing importance on cybersecurity, medical device resilience, procurement transparency, and supply-chain continuity for connected healthcare technologies.

Key Country Insights Across Major Insulin Patch Pump Markets

The United States leads in commercial visibility for tubeless insulin delivery, supported by FDA-cleared systems, private and public payer coverage, broad CGM use, and mature diabetes technology prescribing pathways. Canada follows with strong clinical adoption and guideline-based diabetes care, though provincial reimbursement variation affects patient access. Mexico and Brazil present meaningful need due to large diabetes populations, but access to insulin patch pumps is constrained by affordability, out-of-pocket costs, and public-sector procurement limits.

In Europe, the United Kingdom, Germany, France, Italy, and Spain have mature diabetes care pathways, specialist networks, and reimbursement frameworks, though eligibility criteria, evidence requirements, and regional funding mechanisms differ. Germany and France place strong emphasis on structured reimbursement and clinical evidence, the United Kingdom is shaped by national guidance and local implementation, and Italy and Spain show region-level variation in access. Russia faces additional complexity from procurement, supply-chain constraints, and uneven availability of advanced diabetes technologies.

China and India have vast insulin-requiring populations and rising interest in connected diabetes management, but broad adoption requires tiered pricing, local partnerships, clinician training, and reimbursement progress. Japan, Australia, and South Korea are attractive for connected insulin patch pumps due to advanced healthcare systems, strong digital readiness, clinician familiarity with CGM and pump therapy, and regulatory pathways that support high-quality medical devices. Australia also benefits from structured diabetes support programs, while South Korea and Japan show strong alignment with mobile health and precision device adoption.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinical evidence that demonstrates improvements in time-in-range, hypoglycemia reduction, glycemic variability, treatment satisfaction, patient-reported outcomes, and workflow efficiency. Evidence should include diverse populations, pediatric and adult cohorts where appropriate, and real-world data to support payer negotiations and clinician confidence.

Companies should also design for interoperability, cybersecurity, usability, and affordability from the outset. Practical actions include building CGM-agnostic integration strategies, simplifying onboarding, supporting remote training, offering tiered product portfolios, and strengthening post-market surveillance. Partnerships with endocrinologists, diabetes educators, payers, pharmacies, digital health platforms, and patient support organizations can reduce adoption friction and improve therapy persistence.

Research Methodology

This executive summary is based on secondary research from verified public sources, including international diabetes epidemiology databases, regulatory agency records, peer-reviewed clinical literature, medical device guidance, reimbursement policy references, and recognized public health agencies. Data points were interpreted only where they were supported by identifiable evidence and aligned with published clinical, regulatory, or epidemiological sources.

The methodology emphasizes triangulation across epidemiology, technology adoption, regulatory status, reimbursement environment, and clinical utility. Regional, group, and country insights were assessed through comparable criteria such as diabetes burden, healthcare infrastructure, CGM adoption readiness, payer coverage, device regulation, digital health maturity, affordability barriers, and access to specialist diabetes care.

Conclusion

Insulin patch pumps are becoming an important component of modern diabetes management as care moves toward wearable, connected, and increasingly automated insulin delivery. Their value proposition is strongest when convenience, clinical outcomes, data connectivity, device safety, and payer evidence align.

The next phase of development will depend on validated AI-enabled features, interoperable ecosystems, equitable reimbursement, cybersecurity readiness, and manufacturing resilience. Companies that combine robust clinical evidence with user-centered design and region-specific access strategies will be best positioned to meet sustainable demand in the insulin patch pump market.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Insulin Patch Pumps Market, by Product Type

• 7.1. Disposable Pump
• 7.2. Reusable Pump

8. Insulin Patch Pumps Market, by Diabetes Type

• 8.1. Gestational Diabetes
• 8.2. Type 1 Diabetes
• 8.3. Type 2 Diabetes

9. Insulin Patch Pumps Market, by Operation Mode

• 9.1. Manual
• 9.2. Semi-automated
• 9.3. Fully Automated

10. Insulin Patch Pumps Market, by Wear Duration

• 10.1. Less Than 3 Days
• 10.2. 3 To 5 Days
• 10.3. More Than 5 Days

11. Insulin Patch Pumps Market, by Patient Age Group

• 11.1. Adult
• 11.2. Geriatric
• 11.3. Pediatric

12. Insulin Patch Pumps Market, by End User

• 12.1. Clinics
  • 12.1.1. Diabetes Care Center
  • 12.1.2. Diagnostic Clinic
• 12.2. Home Care
• 12.3. Hospitals

13. Insulin Patch Pumps Market, by Distribution Channel

• 13.1. Offline
• 13.2. Online

14. Insulin Patch Pumps Market, by Region

• 14.1. Asia-Pacific
• 14.2. North America
• 14.3. Latin America
• 14.4. Europe
• 14.5. Middle East
• 14.6. Africa

15. Insulin Patch Pumps Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Insulin Patch Pumps Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025

18. Company Profiles

• 18.1. Abbott Laboratories
• 18.2. Becton Dickinson and Company
• 18.3. Beta Bionics Inc
• 18.4. Bigfoot Biomedical Inc
• 18.5. Braun SE
• 18.6. CeQur SA
• 18.7. Debiotech SA
• 18.8. Diabeloop SA
• 18.9. Eli Lilly and Company
• 18.10. EOFlow Co Ltd
• 18.11. F Hoffmann-La Roche Ltd
• 18.12. Insulet Corporation
• 18.13. MannKind Corporation
• 18.14. Medtronic plc
• 18.15. Medtrum Technologies Inc
• 18.16. MicroPort Scientific Corporation
• 18.17. MicroTech Medical Hangzhou Co Ltd
• 18.18. Modular Medical Inc
• 18.19. Novo Nordisk AS
• 18.20. PharmaSens AG
• 18.21. Sanofi SA
• 18.22. Senseonics Holdings Inc
• 18.23. Sequel Med Tech LLC
• 18.24. SFC Fluidics Inc
• 18.25. SOOIL Development Co Ltd
• 18.26. Tandem Diabetes Care Inc
• 18.27. Terumo Corporation
• 18.28. ViCentra BV
• 18.29. Ypsomed Holding AG